Introduction
============

Mitochondria are essential organelles of eukaryotic cells that participate in several metabolic pathways, cell signaling, and apoptosis ([@bib48]; [@bib51]; [@bib52]). Mitochondria have a very plastic morphology and constantly fuse and divide. Genetic studies in *Drosophila melanogaster* and *Saccharomyces cerevisiae* have led to the identification of components of the enzymatic machineries that bring about mitochondrial fusion and fission ([@bib43]; [@bib2]; [@bib37]; [@bib56]; [@bib26]). Important components of these machineries are members of the family of dynamin-related GTPases ([@bib44]). It has been established that an inner mitochondrial membrane (IMM)-- and outer mitochondrial membrane (OMM)--specific machinery acts during mitochondrial fusion. Specifically, the dynamin-related GTPases Fzo1/Mfn1,2 are required for OMM fusion ([@bib25]; [@bib9]). Conversely, the dynamin-related GTPases Mgm1/Opa1 are required for IMM fusion ([@bib50]; [@bib41]). Recent studies have demonstrated that the role of these proteins is conserved in *Caenorhabditis elegans*. Specifically, the Fzo1/Mfn1,2 homologue, FZO-1, and the Mgm1/Opa1 homologue, EAT-3, are required for mitochondrial fusion in *C. elegans* ([@bib4]; [@bib28]; [@bib31]; [@bib53]). EAT-3/Mgm1/Opa1 also plays a role in mitochondrial cristae structure maintenance ([@bib17]; [@bib40]; [@bib31]). In addition, *C. elegans* EAT-3 has been shown to be required for resistance to oxidative stress caused by free radicals ([@bib31]).

The molecular mechanisms underlying mitochondrial fusion are still unclear. However, with the development of in vitro and in vivo mitochondrial fusion assays, these mechanisms are now being elucidated. Mitochondrial fusion seems to involve four distinct steps: (1) OMM tethering, (2) OMM fusion, (3) IMM tethering, and (4) IMM fusion ([@bib26]). In addition, GTP binding and hydrolysis is required for mitochondrial fusion ([@bib39]). IMM potential is also important for mitochondrial fusion; however, its mechanistic role in the fusion process remains elusive ([@bib39]). The fusion of the OMM and IMM are temporally linked in vivo, indicating the existence of mechanisms to coordinate the OMM and IMM fusion machineries. It has been proposed that the *S. cerevisiae* protein Ugo1, which interacts with both Fzo1 and Mgm1, mediates the coordination of these two events ([@bib49]; [@bib27]). To date, no structural or functional homologue of Ugo1 has been characterized in higher eukaryotes. Thus, how IMM and OMM fusion are coordinated in higher eukaryotes remains to be elucidated.

The mechanisms underlying the regulation of dynamin-related GTPases are starting to be elucidated ([@bib8]). The activity of *S. cerevisiae* Fzo1 is in part controlled by protein degradation ([@bib18]; [@bib42]), and mammalian Opa1 and yeast Mgm1 can be regulated through the generation of different isoforms and by proteolysis ([@bib24]; [@bib13]; [@bib29]). Recently, BCL-2--like proteins, which play critical roles during apoptosis ([@bib58]), have also been implicated in the control of mitochondrial morphology and have been proposed to do so by regulating the activity of dynamin-related GTPases ([@bib30]; [@bib15]; [@bib33]; [@bib7]; [@bib38]; [@bib53]; [@bib3]). All of these regulatory mechanisms are thought to induce appropriate mitochondrial morphology changes in response to certain cellular signals or events such as cell division ([@bib8]).

In this study, we demonstrate that the BCL-2--like protein CED-9 of *C. elegans* can induce complete mitochondrial fusion in a manner that is dependent on the ability of CED-9 to physically interact with the dynamin-related GTPase FZO-1, the *C. elegans* orthologue of Fzo1/Mfn1,2. We propose that CED-9 acts to control and coordinate the fusion of the OMM and IMM in healthy cells in response to specific cellular signals.

Results
=======

CED-9 can promote complete mitochondrial fusion in *C. elegans*
---------------------------------------------------------------

It has been reported that the expression of the *C. elegans ced-9* gene (*ced-9*(wt)) in cultured mammalian cells can promote mitochondrial fusion ([@bib15]). To determine whether the expression of *ced-9*(wt) can also promote mitochondrial fusion in *C. elegans*, we analyzed the effect of *ced-9*(wt) expression on mitochondrial morphology in *C. elegans* embryos. To that end, we used transgenic lines expressing *mitogfp* and *ced-9*(wt) under the control of an inducible promoter and analyzed mitochondrial morphology in transgenic embryos during midgastrulation (∼150 min after the first cell division; we estimate that the level of CED-9 protein in transgenic embryos is about five times higher than the endogenous level). Similar to what we observed in wild-type embryos stained with tetramethyl rhodamine ethyl ester (TMRE; see [Fig. 4 B](#fig4){ref-type="fig"}, row 1), embryos expressing *mitogfp* alone had tubular mitochondria (82%, *n* = 14, four independent transgenic lines; [Fig. 1 B](#fig1){ref-type="fig"}, row 1). In contrast, the majority of embryos expressing *mitogfp* and *ced-9*(wt) had one or two highly globular mitochondria per cell (90%, *n* = 8, three independent transgenic lines; [Fig. 1 B](#fig1){ref-type="fig"}, row 2). A similar phenotype was observed in embryos expressing *mitogfp* and *ced-9*(*n1950*gf) (81%, *n* = 22, three independent transgenic lines; [Fig. S1 B](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1), row 2), indicating that this mutation, which enhances the ability of CED-9 to block apoptosis ([@bib22]), does not compromise the ability of CED-9 to promote mitochondrial fusion. In both cases, 3D reconstruction of z stacks confirmed the presence of one or two highly globular organelles per cell ([Table S1](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) and [Videos 1](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1), [2](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1), and [5](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)).

![**CED-9 promotes FZO-1-- and EAT-3--dependent mitochondrial fusion.** (A) Schematic of the mitochondrial morphologies observed in embryos. (B) Wild-type (+/+), *fzo-1*(*tm1133*), or *eat-3*(*ad426*) transgenic lines expressing *mitogfp* alone (P~HS~*mitogfp*) or in the presence of *ced-9*(wt) (P~HS~*mitogfp* + P~HS~*ced-9*(wt)) were analyzed by Nomarski optics and fluorescent microscopy. Quantification of the different mitochondrial morphologies observed and the number of embryos and transgenic lines analyzed are indicated. The outlines of representative cells are indicated with dashed circles. [Videos 1--4](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) show 3D reconstructions of the embryos marked with asterisks.](JCB_200905070_RGB_Fig1){#fig1}

Unfortunately, the relatively small size of embryonic cells (∼5 μm) prevented us from analyzing the ultrastructure of these highly globular organelles. Therefore, we expressed *ced-9*(wt) in body wall muscle cells and analyzed mitochondrial morphology in these cells in larvae of the fourth larval stage (L4 larvae; at this stage of development, body wall muscle cells are ∼60-μm long and ∼8-μm wide). However, we failed to obtain stable transgenic lines expressing *ced-9*(wt) under the control of a body wall muscle--specific promoter (P*~myo-3~*), suggesting that the constitutive overexpression of *ced-9*(wt) in these cells might be toxic. For this reason, we conditionally expressed *ced-9*(wt) in body wall muscle cells using the Smg-inducible system ([@bib45]). Body wall muscle cells of animals expressing *mitogfp* alone have tubular mitochondria (100%, *n* = 6, one line; [Fig. 2 B](#fig2){ref-type="fig"}, row 1). This result is consistent with previous studies ([@bib28]; [@bib31]; [@bib53]) and with the mitochondrial morphology we observed in wild-type embryos ([Fig. 1](#fig1){ref-type="fig"}). In contrast, after the induction of transgene expression, animals carrying a P*~myo-3~ ced-9*(wt) (3′untranslated region \[UTR\]*smg*) transgene have highly globular mitochondria (50%, *n* = 8, three independent lines; [Fig. 2 B](#fig2){ref-type="fig"}, row 2, arrows). This phenotype is reminiscent of the phenotype observed in embryos ([Fig. 1](#fig1){ref-type="fig"}) and is consistent with previous experiments ([@bib53]). In some cells, we also noticed clusters of mitochondria ([Fig. 2 B](#fig2){ref-type="fig"}, row 3, arrowhead). These clusters, which are very similar to the aggregates induced by *fzo-1* overexpression (57%, *n* = 7, one line; [Fig. 2 B](#fig2){ref-type="fig"}, row 5, arrowheads), could represent fusion intermediates.

![**CED-9 promotes mitochondrial fusion, whereas FZO-1 promotes mitochondrial aggregation in body wall muscle cells.** (A) Schematic of the mitochondrial morphologies observed in body wall muscle cells. (B) Transgenic lines expressing *mitogfp* alone (P*~myo-3~ mitogfp*), in the presence of *ced-9*(wt) (P*~myo-3~ mitogfp* + P*~myo-3~ ced-9*(wt) (3′UTR*smg*)), or in the presence of *fzo-1* (P*~myo-3~ mitogfp* + P*~myo-3~ fzo-1* (3′UTR*smg*)) were grown at 25°C to allow the expression of the *smg*-inducible transgene, as indicated in Materials and methods. These lines, as well as *drp-1*(*RNAi*) animals and *lea-1*(*RNAi*) animals (control(*RNAi*)) carrying a P*~myo-3~ mitogfp* transgene, were analyzed by fluorescent microscopy. Quantification of the different mitochondrial morphologies observed and the number of body wall muscle cells and transgenic lines analyzed are indicated. nuc, nucleus; arrows, fused mitochondria; arrowheads, aggregated mitochondria. Error bars indicate standard deviations.](JCB_200905070_RGB_Fig2){#fig2}

Analysis by EM of cross sections of wild-type body wall muscle cells of L4 larvae revealed mainly small and round mitochondria lying in the muscle belly just below the sarcomere. (12/12 muscle cells, four animals; [Fig. 3 A](#fig3){ref-type="fig"}). In contrast, we found that in a given cross section, *ced-9*(wt) overexpression can induce the formation of one large mitochondrion per cell (2/18 muscle cells, three animals; [Fig. 3 B](#fig3){ref-type="fig"}), whereas *fzo-1* overexpression only induced the formation of clusters of mitochondria (3/14 muscle cells, three animals; [Fig. 3 E](#fig3){ref-type="fig"}). These phenotypes and their respective frequencies of occurrence are consistent with what we observed by fluorescent microscopy ([Fig. 2](#fig2){ref-type="fig"}). We estimate that ∼25% of the muscle cells are mitoGFP positive and therefore express the transgene. Because 50% and 57% of the mitoGFP-positive muscle cells show a phenotype after *ced-9*(wt) or *fzo-1* overexpression, respectively (see previous paragraph), we expected to see alterations in mitochondrial morphology by EM in 12.5% and 14.5% of the cells, respectively. Using morphometric analysis, we confirmed that a subpopulation of mitochondria of *ced-9*(wt)--overexpressing animals have increased thickness (unpublished data). Interestingly, despite their abnormal size, CED-9--induced large mitochondria in general seem to have normal OMM, IMM, and cristae structures. In some cells overexpressing *ced-9*(wt), we observed mitochondrial clusters, which might constitute fusion intermediates (2/18 muscle cells, three animals; [Fig. 3 C](#fig3){ref-type="fig"}). Finally, in one case, we also observed mitochondria composed of multiple concentric layers as described previously by [@bib53]; 1/18 muscle cells, three animals; [Fig. 3 D](#fig3){ref-type="fig"}). This phenotype could be caused by hyper fusion of the OMM. In summary, these results suggest that, as in cultured mammalian cells, the CED-9 protein can promote mitochondrial fusion in *C. elegans*.

![**EM analysis of CED-9--induced mitochondrial fusion and FZO-1--induced mitochondrial aggregation.** (A) Transgenic lines expressing *mitogfp* alone (P*~myo-3~ mitogfp*) show wild-type muscle mitochondria lying just below the sarcomere. Note its abundant internal cristae. (B--D) Transgenic lines expressing *mitogfp* in the presence of *ced-9*(wt) (P*~myo-3~ mitogfp* + P*~myo-3~ ced-9*(wt) (3′UTR*smg*)) show mitochondria with abundant cristae. Three typical structures were observed. (B) Mitochondria form elongated and branched structures. These giant mitochondria seem fused. Nearby tubes may be part of these giant mitochondria; however, in one thin section, it is not possible to know for sure. (C) Mitochondria have smaller diameter and are closely clustered. In some cases, neighboring mitochondria may be physically attached to one another through the OMM. (D) Mitochondria lie closely together, and some show nested profiles in which one tube is completely enveloped by another. Cristae in some cases run circumferentially inside narrow outer tubes. (E) Transgenic lines expressing *mitogfp* in the presence of *fzo-1* (P*~myo-3~ mitogfp* + P*~myo-3~ fzo-1* (3′UTR*smg*)) show mitochondria with abundant cristae, which are closely clustered and tend to have smaller diameters. In many cases, neighboring mitochondria may be physically attached to one another through the OMM. Insets show a magnified view of the indicated area. Bars, 500 nm.](JCB_200905070R_GS_Fig3){#fig3}

CED-9--induced mitochondrial fusion is dependent on FZO-1 and EAT-3
-------------------------------------------------------------------

The dynamin-related GTPases FZO-1 and EAT-3 are required for mitochondrial fusion in *C. elegans* ([@bib4]; [@bib28]; [@bib31]; [@bib53]). To investigate whether the ability of the CED-9 protein to promote mitochondrial fusion is dependent on a functional *fzo-1* or *eat-3* gene, we analyzed transgenic animals carrying loss of function mutations in the *fzo-1* gene (*fzo-1*(*tm1133*)) or the *eat-3* gene (*eat-3*(*ad426*)). Consistent with previous studies, transgenic animals homozygous for these loss of function mutations and expressing *mitogfp* have fragmented mitochondria (100%, *n* = 7, two independent lines; [Fig. 1 B](#fig1){ref-type="fig"}, rows 3 and 5).

We found that *ced-9*(wt) overexpression failed to promote mitochondrial fusion in *fzo-1*(*tm1133*) animals (0%, *n* = 9, three independent lines; [Fig. 1 B](#fig1){ref-type="fig"}, row 4). Instead, in these animals, mitochondria aggregated into one or two large clusters per cell, which is reminiscent of the phenotype caused by *fzo-1* expression (Table S1 and [Videos 3](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) and [8](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). We confirmed that the inability of *ced-9*(wt) expression to promote mitochondrial fusion in *fzo-1*(*tm1133*) embryos was not the result of lower levels of CED-9 protein ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). Interestingly, we found that the level of bc1 protein (a protein of complex III of the electron transport chain) is reduced in *fzo-1*(*tm1133*) animals (Fig. S2 A). This result is consistent with the observation that *fzo-1*(*tm1133*) animals seem to have less active mitochondria when stained with TMRE (unpublished data).

Similarly, we found that *ced-9*(wt) expression failed to promote mitochondrial fusion in *eat-3*(*ad426*) animals (0%, *n* = 8, two independent lines; [Fig. 1 B](#fig1){ref-type="fig"}, row 6; Table S1; and [Video 4](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). Instead, like in *fzo-1*(*tm1133*) animals, *ced-9*(wt) expression in *eat-3*(*ad426*) mutants induced mitochondrial aggregation. Again, the inability of *ced-9*(wt) expression to promote mitochondrial fusion in *eat-3*(*ad426*) embryos was not because of lower levels of CED-9 protein (Fig. S2 B).

We also observed that CED-9(*n1950*gf)--induced mitochondrial fusion was blocked by *fzo-1*(*tm1133*) and *eat-3*(*ad426*) (Fig. S1). Once again, the inability of *ced-9*(*n1950*gf) expression to promote mitochondrial fusion in the *eat-3*(*ad426*) or *fzo-1*(*tm1133*) mutant background was not because of lower levels of CED-9(*n1950*gf) protein (Fig. S2, D and E). Based on these results, we conclude that the CED-9 protein can promote mitochondrial fusion in a manner that is dependent on the dynamin-related GTPases FZO-1 and EAT-3.

*ced-9*(wt) expression might have a weak effect on mitochondrial mass in *C. elegans*
-------------------------------------------------------------------------------------

Overexpression of BCL-x~L~ has been shown to increase mitochondrial mass in cultured mammalian cells 3--10-fold ([@bib3]). Therefore, we investigated whether *ced-9*(wt) overexpression has the same effect in *C. elegans*. To that end, we measured the levels of three mitochondrial proteins by Western analysis: the bc1 protein, cytochrome oxidase I, and the α subunit of ATP synthase (these proteins are part of complexes III, IV, and V of the electron transport chain, respectively). No significant differences in the levels of these proteins were observed in transgenic lines overexpressing *mitogfp* and *ced-9*(wt) when compared with transgenic lines overexpressing *mitogfp* alone (Fig. S2 F). However, analysis of EM pictures revealed that the mitochondrial area is increased by ∼25% in transgenic lines overexpressing *ced-9*(wt) compared with control transgenic lines (Fig. S2 G). Therefore, we conclude that CED-9 might affect mitochondrial mass in *C. elegans* but to a much lesser extent than what has been observed for BCL-x~L~ in mammalian cells.

*ced-9* mutants do not display obvious defects in mitochondrial morphology
--------------------------------------------------------------------------

Based on MitoTracker staining, it has been reported that embryos homozygous for a temperature-sensitive partial loss of function mutation of *ced-9*, *n1653*ts, have fragmented mitochondria ([@bib15]). Based on this observation, it was proposed that *ced-9* plays an important role in mitochondrial fusion. However, we found that in contrast to TMRE, MitoTracker does not label mitochondria in *C. elegans* embryos ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). For this reason, we reexamined mitochondrial morphology in *ced-9* mutants using TMRE. We were unable to detect a defect in mitochondrial morphology in *ced-9*(*n1653*ts) embryos at the nonpermissive temperature (100%, *n* = 7; [Fig. 4 B](#fig4){ref-type="fig"}, row 2). Furthermore, we failed to detect a defect in embryos homozygous for *n2812*, a null allele of the *ced-9* gene (100%, *n* = 10; [Fig. 4 B](#fig4){ref-type="fig"}, rows 4 and 6). However, we cannot exclude that, in the strains analyzed, potential effects of *ced-9* mutations on mitochondrial morphology are suppressed by the presence of secondary mutations. The occurrence of such compensatory, secondary mutations has previously been demonstrated in *S. cerevisiae* ([@bib11]). Therefore, to rule out the possibility that secondary mutations mask a mitochondrial phenotype in *ced-9* mutants, we transiently inactivated the *ced-9* gene by RNAi, which results in reduced CED-9 protein levels (Fig. S2 I). However, we failed to detect any mitochondrial morphology defects after *ced-9* RNAi treatment (100%, *n* = 10; [Fig. 4 B](#fig4){ref-type="fig"}, row 7). We confirmed these results using 3D reconstruction of z stacks of wild-type and *ced-9*(*n1653*ts) embryos (Table S1 and [Videos 6](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) and [7](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). Finally, we also found that the mitochondrial morphology in *ced*-9(*n1950*gf) embryos was indistinguishable from the morphology observed in wild-type embryos (100%, *n* = 10; [Fig. 4 B](#fig4){ref-type="fig"}, row 8).

![**The loss of *ced-9* function does not cause detectable defects in mitochondrial morphology in embryos.** (A) Schematic of the mitochondrial morphologies observed in embryos. (B) Mitochondria of wild-type (+/+), *ced-3*(*n2427*), *ced-9*(*n2812*); *ced-3*(*n2427*), *ced-4*(*n1162*), *ced-9*(*n2812*); *ced-4*(*n1162*), *ced-9*(*n1653*ts), *ced-9*(*RNAi*), and *ced-9*(*n1950*gf) embryos were stained using TMRE, as indicated in Materials and methods. Quantification of the different mitochondrial morphologies observed and the number of embryos analyzed are indicated. [Videos 6](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) and [7](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) show 3D reconstructions of wild-type and *ced-9*(*n1653*ts) embryos marked with asterisks.](JCB_200905070_RGB_Fig4){#fig4}

To elucidate whether the CED-9 protein plays a role in mitochondrial fusion during later stages of development, we analyzed mitochondrial morphology in body wall muscle cells of L4 larvae. Animals homozygous for *ced-9*(*n2812*) do not display a significant fragmented mitochondrial morphology (+/+: 14%, *n* = 133; *ced-3*(*n2427*): 9%, *n* = 151; *ced-9*(*n2812*); *ced-3*(*n2427*): 14%, *n* = 109; [Fig. 5](#fig5){ref-type="fig"}). This result is consistent with previous experiments ([@bib53]). In addition, we found that *ced-9*(*RNAi*) animals do not have a significant fragmented mitochondrial phenotype compared with control RNAi animals (*control*(*RNAi*): 12%, *n* = 42; *ced-9*(*RNAi*): 9%, *n* = 38). In contrast, we confirmed that, as previously shown ([@bib28]), *fzo-1*(*RNAi*) animals have mainly fragmented mitochondria (66%, *n* = 24; [Fig. 5](#fig5){ref-type="fig"}). Western analysis confirmed that CED-9 and FZO-1 protein levels were reduced after *ced-9* and *fzo-1* RNAi treatment, respectively (Fig. S2 I). Using morphometric analysis, we found that *ced-9*(*n2812*); *ced-3*(*n2427*) animals have slightly shorter mitochondria compared with *ced-3*(*n2427*) animals (*ced-3*(*n2427*): 4.2 ± 1.6 μm, *n* = 21; *ced-9*(*n2812*); *ced-3*(*n2427*): 3.5 ± 1.3 μm, *n* = 38; [Fig. S4](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). Similarly, *ced-9*(*RNAi*) animals have slightly smaller mitochondria compared with *control*(*RNAi*) animals. (*control*(*RNAi*): 4.5 ± 1.7 μm, *n* = 11; *ced-9*(*RNAi*): 4.3 ± 1.4 μm, *n* = 24; Fig. S4). Finally, *ced-9*(*n1950*gf) animals have slightly longer mitochondria compared with wild-type animals (+/+: 3.6 ± 1.1 μm, *n* = 25; *ced-9*(*n1950*gf): 4.2 ± 1.5 μm, *n* = 24; Fig. S4). However, in all three cases, the differences were not statistically significant (Fig. S4).

![**The loss of *ced-9* function does not cause detectable defects in mitochondrial morphology in body wall muscle cells.** (A) Schematic of the mitochondrial morphologies observed in body wall muscle cells. (B) Wild-type (+/+), *ced-3*(*n2427*), *ced-9*(*n2812*); *ced-3*(*n2427*), ced*-9*(*RNAi*), *fzo-1*(*RNAi*), and *ced-9*(*n1950*gf) L4 larvae carrying a P*~myo-3~ mitogfp* transgene were analyzed by fluorescent microscopy. Quantification of the different mitochondrial morphologies observed and the number of body wall muscle cells and transgenic lines analyzed are indicated, and quantification of the mitochondrial length is shown in [Fig. S4](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1). nuc, nucleus. Error bars indicate standard deviations.](JCB_200905070_RGB_Fig5){#fig5}

In summary, we conclude that, at least under normal growth conditions and in the absence of internal or external stress, *ced-9* mutants do not display obvious defects in mitochondrial morphology during embryogenesis or in body wall muscle cells during larval development. However, we cannot rule out the idea that *ced-9* mutants exhibit defects in the rate of mitochondrial fusion, which might not necessarily cause significant changes in mitochondrial morphology.

The loss of *ced-9* function partially suppresses embryonic lethality caused by *drp-1* RNAi
--------------------------------------------------------------------------------------------

Animals treated with *drp-1* RNAi have highly elongated and connected mitochondria ([@bib36]). We tested whether *drp-1* RNAi--induced changes in mitochondrial morphology are dependent on the presence of a functional *ced-9* gene. To that end, we analyzed the effect of *drp-1* RNAi on mitochondrial morphology in wild-type animals and *ced-9*(*n2812*) animals. In both cases, we observed highly elongated and connected mitochondria (unpublished data). However, although *drp-1* RNAi induced 26% (± 6.2%, *n* = 309) of embryonic lethality on average in a wild-type background, it only induced 16% (± 2.8%, *n* = 278) of embryonic lethality on average in a *ced-9*(*n2812*) background. Interestingly, like the complete inactivation of *drp-1* by RNAi in the *ced-9*(*n2812*) background, the partial inactivation of *drp-1* by RNAi in a wild-type background also caused highly elongated and connected mitochondria and 9.8% (± 4.1%, *n* = 117) embryonic lethality on average. Thus, an effect on the rates of mitochondrial fusion and fission that does not cause detectable changes in steady-state mitochondrial morphology can cause a detectable increase in embryonic survival. Therefore, it is possible that the suppression of *drp-1* RNAi--induced embryonic lethality by the loss of *ced-9* function is caused by a reduction in the rate of mitochondrial fusion.

The CED-9 protein physically interacts with the FZO-1 protein
-------------------------------------------------------------

To determine whether CED-9 can physically interact with FZO-1 or EAT-3, we used the yeast two-hybrid system. We found that CED-9 can interact with FZO-1 ([Fig. 6 A](#fig6){ref-type="fig"}). We confirmed the interaction in vitro using GST pull-down experiments. Specifically, in vitro--translated, \[^35^S\]methionine-labeled FZO-1 protein copurified with GST-tagged CED-9 (GST∷CED-9) protein but not with GST alone. In vitro--translated, \[^35^S\]methionine-labeled control proteins (luciferase or the yeast protein SSN6p) did not copurify with GST∷CED-9, indicating that the interaction between GST∷CED-9 and FZO-1 is specific ([Fig. 6 B](#fig6){ref-type="fig"}). Similarly, in vitro--translated, \[^35^S\]methionine-labeled CED-9 copurified with GST-tagged FZO-1 (GST∷FZO-1) protein but not with GST alone ([Fig. 6 C](#fig6){ref-type="fig"}). To validate the interaction in vivo, using an anti-GFP antibody, we immunoprecipitated functional FZO-1∷GFP fusion protein or a control GFP fusion protein (GFP∷TRA-4) from lysates generated from transgenic animals expressing *fzo-1∷gfp* or *gfp∷tra-4* under the control of an inducible promoter (P~HS~*fzo-1∷gfp*) or the *tra-4* promoter (P*~tra-4~gfp∷tra-4*). Using a CED-9--specific antibody (Fig. S2 H), we found that endogenous CED-9 coimmunoprecipitated with FZO-1∷GFP but not GFP∷TRA-4 ([Fig. 6 D](#fig6){ref-type="fig"}). Furthermore, endogenous CED-9 was not detected in precipitates from nontransgenic animals, and the anti-GFP antibody failed to coimmunoprecipitate an unrelated protein, NHL-2 ([@bib21]). Therefore, CED-9 can physically interact with FZO-1 in vivo, and this interaction is most probably direct.

![**CED-9 physically interacts with FZO-1.** (A) CED-9 interacts with FZO-1 in yeast. BD, Gal4p-binding domain; AD, Gal4p activation domain. (B and C) CED-9 interacts with FZO-1 in vitro. GST∷CED-9 and GST∷FZO-1 were used in pull-down experiments in the presence of in vitro--translated \[^35^S\]-labeled FZO-1 and CED-9, as described in Materials and methods. (D) CED-9 and FZO-1 interact in vivo. Embryonic lysates from wild-type (N2) animals or animals expressing P*~HS~-fzo-1∷gfp* or P*~tra-4~-gfp∷tra-4* were immunoprecipitated using anti-GFP antibodies, as described in Materials and methods. The precipitated proteins (IP) were analyzed for the presence of endogenous CED-9 or NHL-2 protein. (E) CED-9 interacts with the central domain of FZO-1 predicted to form a coiled-coil structure. The percentage of truncated FZO-1 protein pulled down was normalized to the percentage of full-length FZO-1 protein pulled down (*n* = 2). CC, coiled-coil regions; TM, transmembrane domain. (F) Mutations in the BH2 domain of CED-9 affect its ability to interact with FZO-1. The percentage of FZO-1 pulled down by the GST∷CED-9 mutant was normalized to the percentage of FZO-1 pulled down by GST∷CED-9(wt) (*n* = 6) . \*, P \< 0.0001 by Student\'s *t* test. Error bars indicate standard deviations.](JCB_200905070_GS_Fig6){#fig6}

To identify the domains of FZO-1 required for binding to CED-9, we tested fragments of the FZO-1 protein for their ability to bind to CED-9 in vitro. We found that FZO-1 binds to CED-9 predominantly through its central domain (aa 346--595), which is predicted to form a coiled-coil structure ([Fig. 6 E](#fig6){ref-type="fig"}). In addition, we found that FZO-1 can also bind to CED-9 through its N-terminal part (aa 1--219), which contains the GTPase domain and is predicted to form a coiled-coil structure ([Fig. 6 E](#fig6){ref-type="fig"}). We did not observe a significant interaction between aa 1--375 of the FZO-1 protein and CED-9, suggesting that aa 219--375 might form a domain that antagonizes the interaction between FZO-1 and CED-9. The presence of an inhibitory domain at aa 220--345 would also explain why aa 346--595 of the FZO-1 protein have a stronger affinity for CED-9 than the full-length FZO-1 protein ([Fig. 6 E](#fig6){ref-type="fig"}).

We also found that CED-9 interacts with EAT-3 in vitro and that this interaction is dependent on the N-terminal domain of the EAT-3 protein, which is predicted to form a coiled-coil structure ([Fig. S5, A and B](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). However, we were not able to reproducibly confirm this interaction in vivo, indicating that this interaction might be very weak or transient.

CED-9(R211E, N212G) has reduced affinity for FZO-1
--------------------------------------------------

Two mutant CED-9 proteins, CED-9(N158A, A159G, Q160A) and CED-9(R211E, N212G), have been shown to have reduced affinity for the *C. elegans* CED-4 protein, a known interactor of CED-9 in healthy cells ([@bib57]). We confirmed this using GST pull-down experiments (unpublished data). We then tested CED-9(N158A, A159G, Q160A) and CED-9(R211E, N212G) for their ability to bind to FZO-1 in vitro. We found that compared with wild-type CED-9 protein, the affinity of CED-9(R211E, N212G) for FZO-1 was three times lower. In contrast, the affinity of CED-9(N158A, A159G, Q160A) for FZO-1 was not significantly reduced ([Fig. 6 F](#fig6){ref-type="fig"}). aa 211 and 212 are located at the N terminus of the BH2 domain of CED-9. Therefore, the BH2 domain might play an important role in the interaction between CED-9 and FZO-1. Similarly, CED-9(R211E, N212G) but not CED-9(N158A, A159G, Q160A) has reduced affinity for EAT-3 in vitro (Fig. S5 C).

CED-9--induced mitochondrial fusion is dependent on the ability of CED-9 to interact with FZO-1
-----------------------------------------------------------------------------------------------

Because CED-9(R211E, N212G) has reduced affinity for FZO-1, we tested whether these mutations affect CED-9\'s ability to promote mitochondrial fusion. We used the protein CED-9(N158A, A159G, Q160A) as control protein because it has wild-type affinity with respect to FZO-1 binding but, like CED-9(R211E, N212G), reduced affinity with respect to CED-4 binding. We generated transgenic animals expressing *mitogfp* and either *ced-9*(*N158A*, *A159G*, *Q160A*) or *ced-9*(*R211E*, *N212G*) and analyzed mitochondrial morphology in transgenic embryos. We found that, like *ced-9*(wt) expression, the expression of *ced-9*(*N158A*, *A159G*, *Q160A*) caused the formation of one or two large, highly globular mitochondria per cell (100%, *n* = 10, three independent lines; [Fig. 7 B](#fig7){ref-type="fig"}, top). In contrast, *ced-9*(*R211E*, *N212G*) expression promoted mitochondrial fusion less efficiently. Specifically, it caused the formation of two to four smaller, globular mitochondria per cell (100%, *n* = 10, three independent lines; [Fig. 7 B](#fig7){ref-type="fig"}, bottom). The difference in mitochondrial fusion caused by *ced-9*(*N158A*, *A159G*, *Q160A*) or *ced-9*(*R211E*, *N212G*) expression was not caused by a difference in CED-9 protein level (Fig. S2 C). Therefore, we conclude that the ability of CED-9 to induce mitochondrial fusion is dependent on its ability to interact with FZO-1 but not CED-4.

![**CED-9(R211E, N212G) is less effective in the promotion of mitochondrial fusion.** (A) Schematic of the mitochondrial morphologies observed in embryos. (B) Transgenic lines overexpressing *mitogfp* in combination with *ced-9*(*N158A*, *A159G*, *Q160A*) (P~HS~*mitogfp* + P~HS~*ced-9*(*N158A*, *A159G*, *Q160A*)) or *ced-9*(*R211E*, *N212G*) (P~HS~*mitogfp* + P~HS~*ced-9*(*R211E*, *N212G*)) were analyzed by Nomarski optics and fluorescent microscopy. The outline of cells is indicated in the schematic of the mitochondrial network. Quantification of the different mitochondrial morphologies observed and the number of embryos and transgenic lines analyzed are indicated.](JCB_200905070_RGB_Fig7){#fig7}

The expression of *fzo-1* and *eat-3* is not sufficient to cause mitochondrial fusion
-------------------------------------------------------------------------------------

To determine whether *fzo-1* or *eat-3* expression causes excessive mitochondrial fusion as observed in animals expressing *ced-9*(wt), we generated transgenic animals expressing *mitogfp* with *fzo-1*, *eat-3*, or *fzo-1* and *eat-3* and analyzed mitochondrial morphology in transgenic embryos. Unlike *ced-9*(wt) expression, the expression of *fzo-1* caused the tubular mitochondria to aggregate into one or two large clusters per cell (100%, *n* = 7, two independent lines; [Fig. 8 B](#fig8){ref-type="fig"}, row 1; Table S1; and Video 8). This result was confirmed in body wall muscle cells. Although *ced-9*(wt) overexpression caused a complete mitochondrial fusion ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), *fzo-1* overexpression caused only mitochondrial aggregation ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Surprisingly, the expression of *eat-3* caused mitochondria to fragment (100%, *n* = 12, three independent lines; [Fig. 8 B](#fig8){ref-type="fig"}, row 2; Table S1; and [Video 9](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). Furthermore, like the expression of *fzo-1* alone, the expression of both *fzo-1* and *eat-3* caused mitochondria to aggregate into one or two large clusters per cell (85%, *n* = 7, two independent lines; [Fig. 8 B](#fig8){ref-type="fig"}, row 3; Table S1; and [Video 10](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1)). Finally, the expression of both *fzo-1* and *eat-3* in the absence of a functional *drp-1* gene (i.e., in the *drp-1*(*tm1108*) background) caused many of the transgenic animals to be nonviable (unpublished data). The few embryos that we were able to analyze exhibited a highly elongated and connected mitochondrial morphology similar to the morphology observed in *drp-1*(*tm1108*) embryos expressing *mitogfp* alone (100%, *n* = 5, one independent line; [Fig. 8 B](#fig8){ref-type="fig"}, row 5).

![**Expression of *fzo-1* and *eat-3* does not promote complete mitochondrial fusion.** (A) Schematic of the mitochondrial morphologies observed in embryos. (B) Wild-type (+/+) or *drp-1*(*tm1108*) transgenic lines expressing *mitogfp* in the presence of *fzo-1* (P~HS~*mitogfp* + P~HS~*fzo-1*), *eat-3* (P~HS~*mitogfp* + P~HS~*eat-3*), or both *fzo-1* and *eat-3* (P~HS~*mitogfp* + P~HS~*fzo-1* + P~HS~*eat-3*) were analyzed by Nomarski optics and fluorescent microscopy. Quantification of the different mitochondrial morphologies observed and the number of embryos and transgenic lines analyzed are indicated. The outlines of representative cells are indicated with dashed circles. [Videos 8--10](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1) show 3D reconstructions of the embryos indicated by asterisks.](JCB_200905070_RGB_Fig8){#fig8}

In summary, we conclude that overexpression of the mitochondrial fusion machinery is not sufficient to cause mitochondrial fusion in either a wild-type or *drp-1*--deficient background. However, we cannot completely rule out the possibility that the lethality induced by the expression of *fzo-1* and *eat-3* in the *drp-1*(*tm1108*) background masks a potential fusion phenotype.

Discussion
==========

*ced-9*(wt) expression in *C. elegans* is sufficient to induce FZO-1-- and EAT-3--dependent mitochondrial fusion
----------------------------------------------------------------------------------------------------------------

Members of the family of BCL-2--like proteins have recently been implicated in the regulation of mitochondrial fusion ([@bib8]). For example, the BCL-2--like proteins Bax and Bak have been shown to be required for mitochondrial fusion in mammals ([@bib33]). Furthermore, the *C. elegans* BCL-2--like protein CED-9 has been shown to promote mitochondrial fusion when expressed in cultured mammalian cells ([@bib15]). Recently, CED-9 has also been shown to promote mitochondrial fusion in *C. elegans* body wall muscle cells ([@bib53]). In this study, we confirm that CED-9 can promote mitochondrial fusion in *C. elegans* body wall muscle cells, and we demonstrated that it can also promote mitochondrial fusion in *C. elegans* embryos. In addition, we show that CED-9--induced mitochondrial fusion generates giant mitochondria, which in general have normal OMM, IMM, and cristae structure. Therefore, CED-9 can promote the complete fusion of the OMM and IMM. Furthermore, we demonstrate that CED-9\'s ability to promote mitochondrial fusion is dependent on the genes *fzo-1* and *eat-3*. Specifically, *ced-9*(wt) expression in embryos carrying loss of function mutations in the *fzo-1* or *eat-3* gene failed to cause complete mitochondrial fusion and, instead, caused mitochondrial aggregation.

In contrast, *fzo-1*, *eat-3*, or *fzo-1* and *eat-3* overexpression did not result in the generation of giant mitochondria and therefore presumably did not cause complete fusion of the OMM and IMM. Instead, *fzo-1* overexpression promoted mitochondrial aggregation, which is reminiscent of the phenotype caused by Mfn1,2 expression in cultured mammalian cells ([@bib47]). It has been proposed that by promoting the tethering of mitochondria and the fusion of the OMM, Mfn1,2 acts at an early step during mitochondrial fusion ([@bib34]). Although CED-9 promotes a complete fusion of both membranes, FZO-1 might therefore only cause hyper tethering and/or fusion of the OMM. Surprisingly, both the loss of *eat-3* function and *eat-3* overexpression caused mitochondrial fragmentation. Thus, EAT-3 might have dual roles in fusion and fission in *C. elegans*, as it has been proposed for Opa1 in mammalian cells ([@bib12]; [@bib19]). The mechanism through which Opa1 overexpression causes fission remains elusive. However, it does not seem to be caused by a block in fusion but by Drp1-dependent fission ([@bib10]).

The CED-9 protein promotes mitochondrial fusion by directly interacting with FZO-1
----------------------------------------------------------------------------------

We demonstrate that CED-9 can interact with FZO-1 in yeast, in vitro, and in vivo. In addition, mutations that affect the BH2 domain of CED-9 reduce the affinity of CED-9 for FZO-1. The analysis of the CED-9(R211E, N212G) mutant revealed that the ability of CED-9 to promote mitochondrial fusion is not only dependent on the presence of a functional FZO-1 protein but on the ability of CED-9 to physically interact with it. Furthermore, the identification of the domains of FZO-1 required for the interaction of FZO-1 with CED-9 revealed a domain predicted to form a coiled-coil structure. The function of this domain appears to be evolutionary conserved because Bax and Bak have been shown to interact with Mfn2, and the corresponding domain of Mfn2 has been shown to be required for this interaction ([@bib33]; [@bib7]). The identification of a physical interaction between CED-9 and FZO-1 supports the notion that CED-9 plays a role in mitochondrial fusion. However, several questions remain to be addressed. For example, it is currently unclear how CED-9 regulates the activity of FZO-1. Recent studies have shown that CED-9 in *C. elegans* and BCL-x~L~ in mammals can enhance the GTPase activity of the fission protein DRP-1/Drp1 ([@bib38]; [@bib53]). Therefore, it is possible that CED-9 regulates FZO-1 function and promotes mitochondrial fusion by enhancing the GTPase activity of FZO-1. Alternatively, CED-9 could affect the ability of FZO-1 to dimerize. We found that CED-9 can also interact with EAT-3 in vitro. However, we were not able to reproducibly observe this interaction in vivo, which suggests that it might be very weak or transient.

Based on our results, we speculate that CED-9--induced mitochondrial fusion proceeds through the following sequential steps: (1) CED-9 interacts with FZO-1 to promote mitochondrial tethering and/or OMM fusion, and (2) CED-9--dependent activation of FZO-1 results in the FZO-1--dependent activation of EAT-3 through a mechanism that remains to be elucidated. Alternatively, CED-9 might insert into the OMM and interact with EAT-3 in the intermembrane space to directly promote tethering and/or IMM fusion.

The role of CED-9 in mitochondrial fusion
-----------------------------------------

Our results show that CED-9 can promote complete mitochondrial fusion in *C. elegans* by interacting with the mitochondrial fusion machinery. These results are consistent with previous work by [@bib15] in cultured mammalian cells and by [@bib53] in *C. elegans*. However, our results are in apparent contradiction with recent work from [@bib5], who proposed that CED-9 plays no role in mitochondrial dynamics in *C. elegans*. The discrepancy between their results and our results can possibly be explained by the higher concentration of the P~HS~*ced-9*(wt) transgene used by [@bib5] to generate transgenic lines (25 ng/μl instead of 5 ng/μl in our study). Based on our analyses of body wall muscle cells, the resulting high levels of CED-9 protein might be toxic and therefore cause transgenic animals to be nonviable. [@bib5] selected for transgenic animals that carry stable, integrated transgenes in their genomes. During this process, CED-9--dependent toxicity might have led to the selection of lines generating very low levels of CED-9 protein from the *ced-9*(wt) transgene. This low level of CED-9 might be sufficient to block apoptosis but not to promote mitochondrial fusion. Because [@bib5] did not analyze CED-9 protein levels in their transgenic lines, it remains to be determined how their results relate to the results presented in this study.

Our results also indicate that, unlike FZO-1 and EAT-3, CED-9 does not play a major role in mitochondrial fusion during embryogenesis or in body wall muscle cells during larval development. Indeed, even though *ced-9* loss of function animals have slightly shorter mitochondria and *ced-9*(*n1950*gf) animals have slightly longer mitochondria when compared with control animals, the differences are not statistically significant. Similarly, we found that *ced-9*(*n2812*) can suppress *drp-1* RNAi--induced embryonic lethality, possibly by reducing the rate of mitochondrial fusion. However, we could not detect an effect of *ced-9*(*n2812*) on the mitochondrial morphology phenotype caused by *drp-1* RNAi.

If *ced-9* does not have a major role in mitochondria fusion, what could its physiological role be? We are considering the following four possibilities: (1) the role of *ced-9* in mitochondrial fusion might be redundant with that of one or more additional genes. Thus, the inactivation of *ced-9* alone might not be sufficient to cause a defect in mitochondrial fusion. (2) *ced-9* might play a minor role in mitochondrial fusion during embryogenesis and in body wall muscle cells during larval development. In that case, the loss of *ced-9* function might not cause a detectable phenotype when analyzing steady-state mitochondrial morphology. (3) *ced-9* has previously been shown to promote mitochondrial fission during apoptosis ([@bib30]). Therefore, *ced-9* has both profusion and profission activities. As a consequence, the loss of *ced-9* function might affect both fusion and fission rates, resulting in no net change in steady-state mitochondrial morphology. (4) *ced-9* might play a role in mitochondrial fusion only during certain developmental stages, in specific cell types, or under conditions of stress. Therefore, the loss of *ced-9* function might cause a detectable phenotype only in the presence of such a specific cellular signal. We favor the last two possibilities. Specifically, we propose that in the absence of a specific cellular signal, the CED-9 protein promotes both mitochondrial fusion and fission and that in healthy cells, these opposing activities are balanced. Furthermore, we propose that in response to a specific cellular signal, CED-9 profusion and/or profission activity changes, which affects the balance between fusion and fission and thus mitochondrial morphology. The goal of future studies is to further test this model experimentally and to fully elucidate the physiological role of *ced-9* in mitochondrial dynamics.

*C. elegans* CED-9 is not the only BCL-2--like protein with an apparent role in both mitochondrial fusion and fission. For example, although BCL-x~L~ expression promotes mitochondrial fusion in cultured mammalian cells, it has been shown to be required for mitochondrial fragmentation in neurons ([@bib15]; [@bib38]; [@bib3]). Similarly, depending on the cellular context, Bax and Bak can either promote mitochondrial fusion or fission ([@bib16]; [@bib32], [@bib33]; [@bib7]). Therefore, analyzing the regulation of the opposing roles of BCL-2--like proteins in mitochondrial dynamics represents another future challenge.

Materials and methods
=====================

General methods and strains
---------------------------

*C. elegans* strains were cultured as described previously ([@bib6]). Bristol N2 was used as the wild-type strain. Mutations used in this study are listed below and were described previously by [@bib46] except where noted otherwise: LG I, *smg-1*(*cc546*ts) ([@bib45]); LG II, *fzo-1*(*tm1133*) (National BioResource Project), *dpy-10*(*e128*), and *eat-3*(*ad426*); LG III, *ced-4*(*n1162*), *ced-9*(*n1653*ts), *ced-9*(*n1950*gf), and *ced-9*(*n2812*) ([@bib23]); LG IV, *drp-1*(*tm1108*) (National BioResource Project), *ced-3*(*n717*), and *ced-3*(*n2427*) ([@bib23]); and LG X, *lin-15*(*n765*ts).

Transgenic animals
------------------

For the analysis of mitochondrial morphology in embryos, all plasmids were injected into *lin-15*(*n765*ts) animals using 50 ng/μl pL15EK, which contains the *lin-15*--rescuing fragment, as a coinjection marker. P~HS~*mitogfp* was injected at 1 ng/μl, P~HS~*ced-9*(wt) (pBC876/877), P~HS~*ced-9*(N158A, A159G, Q160A) (pBC636/637), P~HS~*ced-9*(R211E, N212G) (pBC638/639), P~HS~*drp-1* (pBC401/403), and P~HS~*fzo-1* (pBC647/648) at 5 ng/μl, P~HS~*eat-3* (pBC673/674) at 20 ng/μl, and P~HS~*fzo-1∷gfp* (pBC683/684) at 10 ng/μl.

For the analysis of mitochondrial morphology in body wall muscle cells, all plasmids were coinjected with pRF4, which contains the *rol-6*(*su1006dm*) allele, which causes a dominant Rol phenotype (80 ng/μl; [@bib35]). P*~myo-3~ mitogfp* (provided by A. Van der Bliek, University of California, Los Angeles, Los Angeles, CA) was injected at 5 ng/μl, P*~myo-3~ ced-9*(wt) (3′UTR*smg*) (pBC862) at 20 ng/μl, and P*~myo-3~ fzo-1* (*3′UTRsmg*) (pBC863) at 20 ng/μl. For a summary of all the transgenic lines generated for this study, see [Table S2](http://www.jcb.org/cgi/content/full/jcb.200905070/DC1).

Analysis of mitochondrial morphology in embryos using TMRE or MitoTracker staining
----------------------------------------------------------------------------------

Adult animals were grown at 20°C in the presence of 30 μM TMRE (Invitrogen) for 16 h as described previously ([@bib30]) or in the presence of 0.4 μg/ml MitoTracker-CMXRos as described previously ([@bib15]). For *ced-9*(*n1653*ts), adults were grown at 20°C in the presence of TMRE for 12 h and then shifted to 25°C for 4 h.

RNA-mediated interference
-------------------------

RNAi was performed as described previously ([@bib54]). For *ced-9* RNAi, *rrf-3*(*pk1426*) L4 larvae were grown at 15°C on *ced-9* RNAi plates for 24 h and transferred for 16 h onto regular TMRE plates without RNAi. Adults were cut open, and embryos were mounted in M9 medium and analyzed by Nomarski optics and fluorescent microscopy.

Partial inactivation of *drp-1* by RNAi was achieved by mixing the *Escherichia coli* strain producing *drp-1* dsRNA with an *E. coli* strain carrying a mock RNAi plasmid.

Analysis of mitochondrial morphology in body wall muscle cells
--------------------------------------------------------------

Adult Rol animals (transgenic animals) were allowed to lay eggs for 2 h at 20°C and were then removed. Plates were incubated for 2--3 d at 20°C, and Rol L4 larvae of the next (F1) generation were analyzed by Nomarski optics and fluorescent microscopy. For RNAi experiments, Rol L4 larvae were grown on RNAi plates for 24 h at 20°C and transferred to fresh RNAi plates for 2--3 d. Rol L4 larvae of the F1 generation were analyzed by Nomarski optics and fluorescent microscopy. Muscle cells with \>50% of fragmented mitochondria were scored as muscle cells with a mitochondrial fragmentation phenotype. Scoring was performed blind.

Overexpression experiments
--------------------------

L4 larvae from transgenic lines were picked and grown at 20°C for 24 h. Nonmultivulval adults (transgenic animals) were transferred to new plates, allowed to lay eggs for 2 h at 20°C, heat shocked at 32°C for 45 min, and incubated at 20°C for 1 h and 15 min before being removed from the plates. Eggs laid during the 4-h period were mounted in M9 medium and analyzed by Nomarski optics and fluorescent microscopy. Throughout this study, transgenic animals carrying extrachromosomal arrays were used. Those animals are mosaic for the presence of the transgenes and thus the expression of the transgenes. However, the mitochondrial morphology observed in individual mitoGFP-positive cells in a given embryo was in general homogeneous. For this reason, the data are presented as the percentage of embryos showing a certain phenotype.

P*~myo-3~ smg*--inducible system
--------------------------------

This system takes advantage of a temperature-sensitive allele of a component of the Smg RNA surveillance machinery (*smg-1*(*cc546*ts)). In a *smg-1*(*cc546*ts) mutant background, an mRNA with an abnormally long 3′ UTR (3′UTR*smg*) is degraded at the permissive temperature (15°C) but translated at the nonpermissive temperature (25°C). Full-length *ced-9* and *fzo-1* cDNAs were cloned into pPD118.60 (provided by A. Fire, Stanford School of Medicine, Stanford, CA) to construct P*~myo-3~ ced-9*(wt) (3′UTR*smg*) and P*~myo-3~ fzo-1* (3′UTR*smg*). *smg-1*(*cc546*ts) transgenic animals carrying P*~myo-3~ ced-9*(wt) (3′UTR*smg*) or P*~myo-3~ fzo-1*(3′UTR*smg*) were maintained at 15°C and transferred at 25°C to induce the expression of the transgene. L4 larvae of the F1 generation were analyzed by fluorescent microscopy or transmission EM.

Image acquisition and processing
--------------------------------

Imaging was performed at 20°C using a microscope equipped with a 100× 1.3 NA oil lens (Axioskop 2; Carl Zeiss, Inc.) and a charge-coupled device camera (1300; Micromax). A Nomarski and fluorescent z stack of each embryo (0.5 μm/slice) was acquired using MetaMorph software (version 7.1; MDS Analytical Technologies). The same acquisition time was used for each experiment (10 ms for Nomarski, 100 ms for TMRE staining, and 200 ms for mitoGFP). The fluorescent images were deconvoluted (10 iterations) blind using AutoDeblur/AutoVisualize software (version 1.4.1; Media Cybernetics). Images shown in the figures correspond to single planes. Images were inverted, and their contrast was enhanced using Paint Shop Pro X software (Corel). The resulting images were used to generate the schematics of the mitochondrial network. Analysis of mitochondrial length in body wall muscle cells was performed on deconvoluted images using MetaMorph.

Transmission EM
---------------

Wild-type and mutant nematodes were prepared for EM by high pressure freezing (HPM 010; Bal-Tec) and freeze substitution (RMC FS-7500; Boeckeler Instruments) into 1% osmium tetroxide in acetone (2% water added) following a standard protocol ([@bib55]) and embedded in plastic resin (Embed 812; Electron Microscopy Sciences). Semithin sections (0.5--0.75 μm) were cut (MT6000; RMC) and stained with Toluidine blue to determine the location within the fixed animal. When the desired area was located, thin sections (70--90 nm) were collected on 400 mesh 8 U thin-bar grids (EMS400H-Cu). Finally, the grids were stained with 2% methanolic uranyl acetate for 20 min followed by Reynold\'s lead citrate for a maximum of 5 min. Samples were viewed on a transmission electron microscope (1010; JEOL) at 100 kV.

Yeast two-hybrid interactions
-----------------------------

The full-length *fzo-1* cDNA was cloned into the vector pACT2 to create a GAL4 DNA transactivation domain fusion. The full-length *ced-9* cDNA was cloned into the vector pBridge to create a GAL4-binding domain fusion ([@bib1]). Yeast strain Y190 was cotransformed with these plasmids by using standard protocols and transformants selected on SD medium lacking tryptophane and leucine. β-Galactosidase activity was assayed on filters as described previously by [@bib1]. Three independent experiments were performed using three independent clones of each strain.

In vitro interactions
---------------------

In vitro interactions were performed by GST pull-down essentially as described previously ([@bib14]). In brief, GST∷CED-9 was produced in BL21(DE3) cells, extracted with 1 ml of NETN buffer (20 mM Tris-HCl, pH 8, 0.5% NP-40, 100 mM NaCl, and a cocktail of protease inhibitor \[Roche\]) by six sonication pulses of 10 s at 30% power (digital sonifier; Branson) and purified using glutathione agarose beads (GE Healthcare). FZO-1 and EAT-3 were in vitro translated in the presence of \[^35^S\]methionine using the TNT Rabbit Reticulocyte Lysate System (Promega). The binding of \[^35^S\]methionine-labeled FZO-1 or EAT-3 with purified GST∷CED-9 was performed for 4 h at 4°C in 500 μl of binding buffer (30 mM Tris-HCl, pH 7.5, 0.5% Triton X-100, 100 mM NaCl, 2 mM MgCl~2~, 1 mM DTT, 0.5% BSA, and a cocktail of protease inhibitor). Agarose beads were washed three times with 1 ml of binding buffer, one time with 1 ml of binding buffer without BSA, resuspended in Laemmli buffer, and boiled for 5 min. The input and pull-down were analyzed by SDS-PAGE and autoradiography using a Storm Imager (GE Healthcare). For GST∷FZO-1, the *fzo-1* cDNA was cloned into the pGEX-4T-3, expressed in BL21(DE3) cells, and purified using the FZO-1 extraction buffer (30 mM Tris-HCl, pH 7.5, 1% Triton X-100, 100 mM NaCl, 2 mM MgCl~2~, 1 mM DTT, and a cocktail of protease inhibitor).The binding of \[^35^S\]methionine-labeled CED-9 with purified GST∷FZO-1 was performed as described for the binding of \[^35^S\]methionine-labeled Fzo1 with GST∷CED-9.

In vivo interactions
--------------------

In vivo interactions were performed by coimmunoprecipitation essentially as described previously ([@bib20]). In brief, embryos from N2 animals and transgenic animals expressing *fzo-1∷gfp* or *gfp∷tra-4* were resuspended in 1 vol of 2× coimmunoprecipitation buffer (100 mM Tris-HCl, pH 7.5, 2% Triton X-100, 200 mM NaCl, 4 mM MgCl~2~, 2 mM DTT, and a cocktail of protease inhibitor) and homogenized by sonicating six times for 10 s at 30% power (digital sonifier; Branson). Immunoprecipitations were performed with monoclonal anti-GFP antibody (anti-AFP; mAb 3E6; MP Biomedicals) for 2 h at 4°C. Immunoprecipitates were captured using 20 μl protein A--Sepharose beads (GE Healthcare) for 1 h at 4°C, washed three times with 1 ml of coimmunoprecipitation buffer, eluted with 20 μl of Laemmli buffer, and boiled for 5 min. The immunoprecipitates and the input were analyzed by SDS-PAGE. To detect CED-9, we used a rabbit polyclonal anti--CED-9 antibody (1:2,000). To detect NHL-2, we used rabbit polyclonal anti--NHL-2 antibody (1:5,000; [@bib21]).

Online supplemental material
----------------------------

Fig. S1 shows that *ced-9*(*n1950*gf) promotes FZO-1-- and EAT-3--dependent mitochondrial fusion. Fig. S2 shows Western analyses of the different transgenic lines used in this study. Fig. S3 shows MitoTracker versus TMRE mitochondrial staining of embryos. Fig. S4 shows the analysis of mitochondrial length in body wall muscle cells of different mutant strains. Fig. S5 shows that CED-9 interacts with EAT-3 in vitro. Videos 1--10 were generated from the z stacks of the embryos after 3D reconstruction using AutoDeblur/AutoVisualize software. A description of the transgenic embryos shown in the videos is indicated in Table S1. A description of the transgenic lines used in this study is indicated in Table S2. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200905070/DC1>.
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